All‐cause mortality formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal SAE ‐ Adults · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality · children with chronic asthma
1 finding from 1 review
Non‐fatal serious adverse events · children with chronic asthma
Children: formoterol/fluticasone showed no clear difference in all‐cause non‐fatal serious adverse events compared with salmeterol/fluticasone (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children with chronic asthma
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention leads to higher SAEs ‐ formoterol versus placebo ( (high certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus salbutamol ( · patients with chronic asthma
The intervention showed no clear difference in SAEs ‐ formoterol versus salbutamol ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (all‐cause) ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus placebo ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (all‐cause) ‐ formoterol versus salbutamol ( · patients with chronic asthma
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus salbutamol ( (moderate certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus placebo ( · patients with chronic asthma (children)
The intervention leads to higher SAEs ‐ formoterol versus placebo ( (high certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus salbutamol · patients with chronic asthma (children)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review